Rare disease-focused Ovid Therapeutics Inc. has paused development of its investigational Angelman syndrome therapy, OV-101, after initial phase III results showed no difference between the drug and a placebo.
The drug-eluting balloon (DEB) has not displaced the drug-eluting stent (DES) for treatment of infarcts, but that may be changing with the results of the PICCOLETO II study.
The already intriguing IL-2 pathway as a therapeutic target gained still more traction after San Francisco-based Nektar Therapeutics Inc. unveiled melanoma data with bempegaldesleukin (bempeg), its CD122-preferential agent in the class.
New York-based Hookipa Pharma Inc.’s positive interim data from a phase II study with what could become the first approved cytomegalovirus (CMV) vaccine, HB-101, lifted shares (NASDAQ:HOOK) to a high of $13.25 early in the day but the price leveled off later to close Nov. 30 at $11.60.
Data from a newly published case series underscores the effectiveness of Cytosorbents Corp.’s blood purification technology in treating critically ill COVID-19 patients.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Ascentage, Celltrion, Equillium, Inmed, Karyopharm, Medicinova, Urovant.
LONDON – Efficacy data for Russia’s Sputnik V COVID-19 vaccine held steady at 91.4% in the second interim analysis, conducted after 39 confirmed cases of COVID-19 infection in 18,794 volunteers, seven days after they received the second dose.
RSS
